摘要
目的探讨阿托伐他汀在心肌梗死后无症状心衰患者中的临床治疗效果。方法选取我院2012年1月至2014年6月收治的80例心肌梗死后无症状心衰患者,随机分为两组各40例。对照组采用常规方案治疗,研究组在对照组的基础上给予阿托伐他汀治疗,比较两组患者治疗后的左心室射血分数(LVEF)、左心室舒张末期内径(LVEDD)、左心室收缩末期内径(LVESD),以及治疗前后的血浆氨基末端利钠肽前体(NT-pro BNP)水平。结果治疗后,研究组的LVEF显著高于对照组,LVEDD及LVESD显著低于对照组,差异具有统计学意义(P<0.05)。治疗前,两组的血浆NT-pro BNP水平无统计学差异(P>0.05);治疗后,研究组NT-pro BNP水平显著低于对照组,差异具有统计学意义(P<0.05)。结论阿托伐他汀对于心肌梗死后无症状心衰具有显著的疗效,可有效改善患者的心功能及血浆NT-pro BNP水平。
Objective To explore the curative effect of atorvastatin for the treatment of patients with symptomless heart failure after myocardial infarction. Methods Eighty patients with symptomless heart failure after myocardial infarction in our hospital from January 2012 to June 2014 were selected and randomly divided into two groups equally. The control group received routine treatment program, while the study group received atorvastatin therapy on the basis of routine treatment. The left ventricular ejection fraction（LVEF）, left ventricular end-diastolic diameter（LVEDD）, left ventricular end-systolic diameter（LVESD） after treatment, and the NT-pro BNP levels before and after treatment were compared between two groups. Results After treatment, the LVEF of study group was significantly higher than that of control group, and the LVEDD and LVESD were significantly lower than those of control group（all P〈0.05）. Before treatment, no statistical difference was found between two groups in the NT-pro BNP level（P〉0.05）, while after treatment, the NT-pro BNP level of study group was significantly lower than that of control group（P〈0.05）. Conclusions Atorvastatin has significant effect for patients with symptomless heart failure after myocardial infarction. It can effectively improve patients＇ heart function and reduce the plasma NT-pro BNP level.
出处
《临床医学工程》
2016年第3期313-314,共2页
Clinical Medicine & Engineering
关键词
心肌梗死
无症状心衰
阿托伐他汀
治疗效果
Myocardial infarction
Symptomless heart failure
Atorvastatin
Curative effect
